Humira

New Zealand - English - Medsafe (Medicines Safety Authority)

Buy It Now

Active ingredient:
Adalimumab 100 mg/mL;  ;  ;  
Available from:
AbbVie Limited
Dosage:
20 mg/0.2mL
Pharmaceutical form:
Solution for injection
Composition:
Active: Adalimumab 100 mg/mL       Excipient: Mannitol Polysorbate 80 Water for injection
Prescription type:
Prescription
Therapeutic indications:
Rheumatoid Arthritis Humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. This includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. Humira can be used alone or in combination with methotrexate.
Product summary:
Package - Contents - Shelf Life: Syringe, glass, (Type I), with a bromobutyl rubber stopper, plunger rod and needle, 0.2 mL fill - 2 dose units - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light 14 days not refrigerated stored at or below 25°C protect from light
Authorization number:
TT50-6735/1d
Authorization date:
2018-05-02

Similar products

Search alerts related to this product

Share this information